General introduction
The importance of the clinical endpoint
Truth table. Sensitivity, specificity, prevalence &
predictive value
Problems with defining test performance
The effectiveness of sample pooling where prevalence is low
Sampling
Tissue culture growth of C. trachomatis and C. pneumoniae
Direct detection in clinical material
Antigen detection immunoassay
Chlamydia Rapid Test and others
Micro IF and EIA for chlamydial antibody testing
When do we need serodiagnosis rather than direct detection?
Hybridisation with signal amplification: Gen-Probe Pace 2
Introduction to nucleic acid or primer amplification
Roche Amplicore ®
CT/NG Cobas Amplicore ®
Abbott LCx ® ligase chain reaction. Now withdrawn.
Real time PCR-based replacement for the Abbott LCx but you have to wait
Strand displacement amplification: BD ProbeTecET ®
First generation Transcription Mediated Amplification: Gen-Probe AMP CT®
Second generation TMA: Gen-Probe Aptima Combo 2®
Teknika Organon NucliSens ®
Self collected or non invasive samples
Use of NAA tests for chlamydia DNA at cervical cancer screen
Adaptation of laboratory robotics equipment, Jim Guthrie, Glasgow
Future trends. Microarrays.
C. trachomatis and N. gonorrhoeae, Oct 2002.
Today's research is tomorrow's routine
Reviewed by Tina Mygind
Presentation by Matthias Horn
Doxycycline therapy
Erythromycin and other macrolides. Azalide. Ketolide
The quinolones
Rifampin, ansamycins, Rifalazil
Beta lactam antibiotics
Antibiotic resistance in C. trachomatis and C. suis
Presentation by Dr Geoffrey Ridgway
Courtesy of Dr Angelika Stary
CDC STI treatment recommendations. May 2002
Linking to treatment sections of infections and syndromes
Main treatment index
Chlamydial infections by syndrome
Index to the professional site
|
